The hallucinogenic world of tryptamines: an updated review

Araújo and colleagues place tryptamine hallucinogens in the context of a rapidly changing recreational drug market, where new psychoactive substances have proliferated as legal or grey-market alternatives to classical drugs such as LSD. The authors note that tryptamines form a broad class of serotonergic (classical) hallucinogens that act primarily at 5-HT2A receptors and include long-used natural compounds (for example psilocybin and DMT, as components of sacred mushrooms and ayahuasca) as well as many more recently synthesised analogues (for example AMT, 5-MeO-DMT, 5-MeO-DIPT) that have become available as “research chemicals” or “legal highs.” The review sets out to provide a comprehensive update on tryptamine hallucinogens, covering historical background, prevalence and patterns of use, legal status, chemistry, toxicokinetics and toxicodynamics, and physiological and toxicological effects in animals and humans. The authors emphasise that information on many new tryptamine derivatives is scarce and that this lack of data impedes assessment of their public‑health risks, motivating the present synthesis of the available literature.

This paper is a narrative review synthesising chemical, pharmacological and toxicological information on known tryptamine hallucinogens. The extracted text does not clearly report a formal literature search strategy, such as databases searched, date ranges, inclusion or exclusion criteria, or a study selection flow; therefore it appears to be a conventional, non‑systematic review rather than a systematic review or meta‑analysis. Instead of specifying search methods, the review is organised topically. Major topics examined include the historical evolution from natural to synthetic tryptamines, patterns of use and prevalence, chemical classification and structure–activity relationships, common routes of administration, typical doses and durations of effect, metabolic pathways and key metabolites, receptor interactions and toxicodynamics, animal behavioural and physiological studies, and reported human subjective effects, adverse reactions and fatalities. Where available, the authors integrate animal experiments, in vitro metabolism and receptor binding data, case reports and observational surveys to draw conclusions about pharmacology and risks.

Historical and epidemiological findings: The review recounts the long ethnobotanical use of natural tryptamines (for example ayahuasca and psilocybin mushrooms) and traces the expansion of synthetic and semi‑synthetic tryptamines since mid‑20th century chemists such as Shulgin. The market for new psychoactive substances has expanded rapidly, with dozens of new tryptamine derivatives appearing; the authors cite increases in identifications in Europe and note that tryptamine users tend to be young adults and predominantly male (studies cited report mean ages in the late teens to late twenties and male predominance up to 86%). Availability via Internet vendors and “headshops”, low price (reported examples 3€ per dose versus 9€ for LSD in Europe), and the desire to experiment are presented as drivers of use. Chemistry and structure–activity relationships: Tryptamines are described as indolamine hallucinogens that structurally resemble serotonin; they contrast with phenylalkylamine hallucinogens. The indole nucleus is the principal feature conferring hallucinogenic activity, with common substitutions at positions 4 and 5 (hydroxy or methoxy) increasing potency. N‑alkyl substituents and α‑methylation affect oral activity and lipophilicity: many N,N‑dialkyl derivatives are orally active, whereas unsubstituted primary‑amine tryptamines are generally inactivated by monoamine oxidase (MAO). Synthetic routes are described as relatively straightforward and information widely available online. Routes, doses and durations: Natural mushrooms are consumed orally (raw or tea). Synthetic tryptamines are taken orally, intranasally, smoked, or injected depending on compound. Typical dose and duration ranges reported include: psilocybin oral doses in adults commonly above ~15 mg with onset 20–40 min and duration 4–6 h (i.v. doses 1–2 mg with very rapid onset and short duration); pure psilocin oral doses 6–20 mg, duration 4–8 h; DMT smoked typical doses ~40–50 mg with very rapid onset and effects <30 min, i.v. 0.1–0.4 mg/kg; 5‑MeO‑DMT active at much lower smoked/parenteral doses (3–5 mg); 5‑MeO‑DALT oral 12–25 mg with 2–4 h duration. The authors highlight that co‑administration with MAO inhibitors (for example ayahuasca β‑carbolines) markedly alters oral bioavailability and duration. Metabolism and toxicokinetics: The review summarises available metabolic data showing that tryptamine metabolism is compound‑dependent. Many simple tryptamines (DMT, 5‑MeO‑DMT, bufotenine) undergo rapid oxidative deamination by MAO‑A to indole‑3‑acetic acid (IAA) derivatives, explaining oral inactivity of DMT unless MAO is inhibited. Alternative routes include N‑oxidation, N‑demethylation and cyclisation; DMT‑N‑oxide and N‑methyltryptamine (NMT) are reported metabolites. Co‑ingestion with MAO inhibitors shifts metabolism away from MAO‑dependent pathways and increases parent drug exposure. For some synthetic derivatives (for example 5‑MeO‑DIPT) specific CYP enzymes (notably CYP2D6 for O‑demethylation and CYP1A1 for certain hydroxylations) have been implicated; hydroxylated metabolites are often eliminated as sulfate or glucuronide conjugates. The authors note that for many newer analogues metabolic pathways and enzyme contributions remain poorly characterised. Receptor pharmacology and toxicodynamics: Tryptamine hallucinogens generally act as agonists at serotonin 5‑HT2A receptors, the principal mediator of classical hallucinogenic effects in humans and in animal behavioural paradigms. Many tryptamines also bind other serotonin subtypes (5‑HT1A, 5‑HT2C) and non‑serotonergic targets: DMT shows activity at σ1 receptors and can interact with trace amine‑associated receptors (TAAR), VMAT2 and SERT, although these are not proposed as primary mediators of classic hallucinations. Affinity profiles vary across derivatives (for example 5‑MeO‑DIPT has higher 5‑HT1A affinity). Animal behavioural and physiological findings: Drug discrimination, head‑twitch and locomotor studies support 5‑HT2A‑mediated hallucinogenic action. Tryptamines produce discriminative stimulus generalisation with LSD and other classical hallucinogens. Head‑twitch responses and other hallucinogen‑typical behaviours are blocked by 5‑HT2A antagonists. Effects on locomotion are context‑dependent (novel vs familiar environment) and can include initial hypolocomotion with later hyperactivity depending on compound and dosing; thermoregulatory disturbances (hypothermia during dosing followed by rebound hyperthermia) and elevated corticosterone have been reported. Repeated or developmental exposure to some tryptamines (notably 5‑MeO‑DIPT) produced later impairments in certain spatial or attentional tasks in rodents and altered serotonergic markers. Human subjective effects, adverse events and fatalities: In humans, tryptamines produce pronounced perceptual and cognitive alterations (visual/auditory hallucinations, distortions of time and self, depersonalisation), with stimulant properties more pronounced for α‑methylated tryptamines. Acute adverse effects include agitation, psychosis or prolonged psychiatric reactions in susceptible individuals, autonomic changes (tachycardia, hypertension, tachypnea), hyperthermia, and rare reports of seizures. Serious medical complications reported include rhabdomyolysis and renal failure. Fatalities associated with specific compounds are described: a 5‑MeO‑DIPT overdose with post‑mortem concentrations reported; an AMT‑associated fatality; and a death following very high intranasal 5‑MeO‑DALT exposure linked to risky behaviour. Co‑use with MAO inhibitors raises the risk of serotonin toxicity and can convert otherwise orally inactive compounds into potent systemic exposures. Treatment for intoxication is supportive and symptomatic; benzodiazepines for agitation, cardiovascular management as needed, and activated charcoal for recent oral ingestions are discussed.

Araújo and colleagues interpret the assembled literature as showing that tryptamine hallucinogens represent a heterogeneous group with shared 5‑HT2A‑mediated hallucinogenic actions but diverse pharmacokinetic and receptor profiles that influence potency, duration and risk. They place particular emphasis on the growing availability of synthetic tryptamines, the paucity of controlled human data for many newer analogues, and the consequent uncertainty about acute toxicity, long‑term effects, drug–drug interactions and addictive potential. The authors compare natural and synthetic tryptamines, noting that although some natural compounds have longstanding ritual or therapeutic contexts, synthetic derivatives have often been adopted recreationally because of accessibility, lower cost and perceived legality. They highlight that metabolic interactions—most notably inhibition of MAO‑A by β‑carbolines in ayahuasca—fundamentally alter disposition and effects and can increase toxicity risk when combined intentionally or inadvertently. Key limitations acknowledged by the authors include the scarce experimental and clinical data for many new tryptamine derivatives, reliance on animal models and user reports for much of the evidence, and limited knowledge of specific metabolic enzymes and quantitative toxicokinetic parameters for many compounds. These gaps, they argue, constrain risk assessment and public‑health responses. Consequently, the authors call for more pharmacological, metabolic and toxicological research on newer tryptamines, improved surveillance of use and harms, and attention from regulatory and clinical communities to emerging compounds and their interactions.

The authors conclude that while classical tryptamines have long histories of use, the recent proliferation of synthetic tryptamine derivatives poses emergent public‑health challenges. Available evidence indicates strong 5‑HT2A activity across many tryptamines and documents cases of severe intoxication and deaths, yet substantial knowledge gaps remain regarding acute and chronic effects, interactions and metabolic pathways. Araújo and colleagues recommend further research to characterise the pharmacology and toxicology of these substances in order to better assess their hazards and inform clinical and policy responses.